Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Nauck, Michael, Frid, Anders, Hermansen, Kjeld, Shah, Nalini S., Tankova, Tsvetalina, Mitha, Ismail H., Zdravkovic, Milan, Düring, Maria +2 more·2009·Diabetes Care

DOI 10.2337/dc08-1355

Cited by (999)

Items 401–500 of 999

Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes
Tadashi Iwao, Kenji Sakai, Michio Sata · 2012 · Journal of Diabetes and its Complications
Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
Manfredi Rizzo, Dragana Nikolić, Maciej Banach, Angelo Maria Patti, Giuseppe Montalto, Ali Abbas Rizvi · 2014 · Current Pharmaceutical Design
Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26‐week, open‐label, randomized, active comparator clinical trial
Li Zang, Y. Liu, Jin Geng, Yuan Ming Luo, Fang Bian, X. Lv, Jian Yang, Jing Liu, Yan Peng, Yanrong Li et al. · 2016 · Diabetes Obesity and Metabolism
Liraglutide-associated acute pancreatitis
Emily L. Knezevich, Theresa Crnic, Scott Kershaw, Andjela Drincic · 2012 · American Journal of Health-System Pharmacy
Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research
Oliver Schnell, Katharine D. Barnard, Richard M. Bergenstal, Emanuele Bosi, Satish K. Garg, Bruno Guerci, Thomas Haak, Irl B. Hirsch, Linong Ji, Sashank R. Joshi et al. · 2015 · Diabetes Care
Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus
Mala Dharmalingam, Usha Sriram, ManashP Baruah · 2011 · Indian Journal of Endocrinology and Metabolism
Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved
Trenson, Liesbet, Trenson, Sander, van Nes, Falco, Moyson, Carolien, Lannoo, Matthias, Deleus, Ellen, Meulemans, Ann, Matthys, Christophe, Mertens, Ann, Van der Schueren, Bart et al. · 2022 · Obesity Facts
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Daria Jaarah, Mazhar Salim Al Zoubi, Gamal T. Abdelhady, Firas Rabi, Murtaza M. Tambuwala · 2021 · Clinical Medicine Insights Endocrinology and Diabetes
Metformin mitigates amyloid β1-40-induced cognitive decline via attenuation of oxidative/nitrosative stress and neuroinflammation
Mahmoud Khaleghi-Mehr, Alireza-Azizzadeh Delshad, Sepideh Shafie-Damavandi, Mehrdad Roghani · 2023 · Metabolic Brain Disease
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects
Börje Darpö, Philip T. Sager, Leigh MacConell, Brenda B. Cirincione, Malcolm I. Mitchell, Jenny Han, Wenying Huang, Jaret L. Malloy, Christine T. Schulteis, Larry Zaiqian Shen et al. · 2012 · British Journal of Clinical Pharmacology
Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists
Katrine Bagge Hansen, Filip Krag Knop, Jens Juul Holst, Tina Vilsbøll · 2009 · International Journal of Clinical Practice
Dosing Rationale for Liraglutide in Type 2 Diabetes Mellitus: A Pharmacometric Assessment
Steen H. Ingwersen, Manoj Khurana, Rajanikanth Madabushi, Estelle Watson, Daniël Martijn Jonker, Tu D. L. Thi, Lisbeth Vestergård Jacobsen, Christoffer Wenzel Tornøe · 2011 · The Journal of Clinical Pharmacology
Incretin Therapies: Effects Beyond Glycemic Control
Sunder Raj D. Mudaliar, Robert R. Henry · 2009 · The American Journal of Medicine
Vildagliptin vs liraglutide as a second‐line therapy switched from sitagliptin‐based regimens in patients with type 2 diabetes: A randomized, parallel‐group study
Takeshita, Yumie, Takamura, Toshinari, Kita, Yuki, Otoda, Toshiki, Kato, Ken‐ichiro, Wakakuri, Hitomi, Yamada, Masayuki, Misu, Hirofumi, Matsushima, Yukiko, Kaneko, Shuichi et al. · 2015 · Journal of Diabetes Investigation
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
Timothy Reid · 2012 · Clinical Diabetes
Retrospective analysis of safety and efficacy of insulin‐to‐liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β‐cell function
Ryota Usui, Daisuke Yabe, Hitoshi Kuwata, Shuichi Fujiwara, Koin Watanabe, Takanori Hyo, Akihiro Yasuhara, Masahiro Iwasaki, Naomi Kitatani, Kyoko Kuwabara et al. · 2013 · Journal of Diabetes Investigation
Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis
Takeyuki Hiramatsu, Akiko Ozeki, Kazuki Asai, Marie Saka, Akinori Hobo, Shinji Furuta · 2015 · Therapeutic Apheresis and Dialysis
Pancreatitis: A Potential Complication of Liraglutide?
Franks, Andrea S, Lee, Phillip H, George, Christa M · 2012 · Annals of Pharmacotherapy
Liraglutide for the treatment of type 2 diabetes
D Shyangdan, Eleanor Cummins, Pamela Royle, Norman R Waugh · 2011 · Health Technology Assessment
Incretin-based therapies for obesity treatment
Aline Haas de Mello, Morgana Dal Prá, Larissa Colonetti Cardoso, Rosiane de Bona Schraiber, Gislaine Tezza Rezin · 2015 · Metabolism
Clinical Management of Elderly Patients with Type 2 Diabetes Mellitus
Richard E. Pratley, Matthew Philip Gilbert · 2012 · Postgraduate Medicine
COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA
Lan Gao, Fei-Li Zhao, Shu‐Chuen Li · 2012 · International Journal of Technology Assessment in Health Care
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial ( BEGIN : ADD TO GLP ‐1 S tudy)
Vanita R. Aroda, Timothy Silleck Bailey, Bertrand Cariou, Sudhesh Kumar, LA Leiter, Philip Raskin, Jeppe Zacho, T. H. Andersen, Athena Philis‐Tsimikas · 2016 · Diabetes Obesity and Metabolism
Fighting Diabetes Mellitus: Pharmacological and Non-pharmacological Approaches
Xin Wang, Jinhong Kang, Qing Liu, Tao Tong, Helong Quan · 2020 · Current Pharmaceutical Design
Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression
Yimin Shao, Geheng Yuan, Junqing Zhang, Xiaohui Guo · 2015 · Drug Design Development and Therapy
The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective
Manfredi Rizzo, Dragana Nikolić, Maciej Banach, Rosaria Vincenza Giglio, Angelo Maria Patti, Vittoria Di Bartolo, Annamaria Tamburello, Antonella Zabbara, G Pecoraro, Giuseppe Montalto et al. · 2013 · Clinical Lipidology
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Zhixia Li, Yuan Zhang, Xiaochi Quan, Zhirong Yang, Xian‐Tao Zeng, Linong Ji, Feng Sun, Siyan Zhan · 2016 · PLoS ONE
Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial
Yutaka Seino, Mads Frederik Rasmussen, Tomoyuki Nishida, Kohei Kaku · 2011 · Journal of Diabetes Investigation
Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials
Matteo Monami, Ilaria Dicembrini, Besmir Nreu, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci · 2017 · Acta Diabetologica
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes
R. Ravi Shankar, Philip Scott Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia, Ron S. Newfield, Ю. Г. Самойлова, Carmen A. Rosario, Naim Shehadeh, Chandan Saha et al. · 2021 · Pediatric Diabetes
Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
Jonathan H. Pinkney · 2010 · Therapeutics and Clinical Risk Management
Cardiovascular Effects of the New Weight Loss Agents
Matthew Vorsanger, Pritha Subramanyam, HOWARD S. WEINTRAUB, Steven H. Lamm, James A. Underberg, Eugenia Gianos, Ira J. Goldberg, Arthur Z. Schwartzbard · 2016 · Journal of the American College of Cardiology
Pharmacological Treatment of Obesity
Dhiraj G. Kabra, Uma Dhiraj Kabra, Matthias H. Tschöp, Susanna M. Hofmann · 2012 · Springer eBooks
GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance
Ngabea, Murtala A, Dimeji, Igbayilola Yusuff · 2025 · Biochemical and Biophysical Research Communications
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer
Chalmer, Thor, Almdal, Thomas P, Vilsbøll, Tina, Knop, Filip K · 2015 · Expert Opinion on Drug Safety
Selective targeting of glucagon‐like peptide‐1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes
Tate, Mitchel, Chong, Aaron, Robinson, Emma, Green, Brian D, Grieve, David J · 2015 · British Journal of Pharmacology
Patient‐reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open‐label study
Wolfgang Ekkehard Schmidt, Jens Sandahl Christiansen, Mette Hammer, Marcin Zychma, John B. Buse · 2011 · Diabetic Medicine
Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
Åke Sjöholm · 2010 · Pharmaceuticals
The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials
Fan Zhang, Hao Xiang, Yunzhou Fan, Tsend-ayush Ganchuluun, Wenhua Kong, Qian Ouyang, Jingwen Sun, Beibei Cao, Hongbo Jiang, Shaofa Nie · 2013 · Endocrine
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Lawrence Blonde, Eduard Montanya · 2012 · Diabetes Obesity and Metabolism
Complementing Insulin Therapy to Achieve Glycemic Control
Anthony H Barnett · 2013 · Advances in Therapy
Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies
Daniel Addison, David A. Aguilar · 2010 · Current Atherosclerosis Reports
Comparable Liraglutide Pharmacokinetics in Pediatric and Adult Populations with Type 2 Diabetes: A Population Pharmacokinetic Analysis
Kristin C. Carlsson Petri, Lisbeth Vestergård Jacobsen, David J. Klein · 2015 · Clinical Pharmacokinetics
Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors
Cassie L. Boland, Michelle DeGeeter, Donald S. Nuzum, Maria Tzefos · 2013 · Annals of Pharmacotherapy
Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances
Kamlesh K. Khunti, Melanie Jane Davies · 2009 · Diabetes Obesity and Metabolism
Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
Ying Liu, Xia Jiang, Xin Chen · 2017 · Lipids in Health and Disease
Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study
Ravassa, Susana, Beaumont, Javier, Huerta, Ana, Barba, Joaquín, Coma-Canella, Isabel, González, Arantxa, López, Begoña, Díez, Javier · 2015 · Free Radical Biology and Medicine
The Role of Incretin Therapy at Different Stages of Diabetes
Simona Cernea · 2011 · The Review of Diabetic Studies
Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide
Tina Vilsbøll, Alan J. Garber · 2012 · Diabetes Obesity and Metabolism
Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin
Antonio Pérez, Pedro Mezquita Raya, Antonio Ramírez de Arellano, Teresa Briones, Barnaby Hunt, William J. Valentine · 2015 · Diabetes Therapy
Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T‐emerge 7 study)
Priscilla A. Hollander, Ben Lasko, Anthony H Barnett, Monica Bengus, Linda Kanitra, F. Xavier Pi‐Sunyer, R. Balena · 2013 · Obesity
Liraglutide counteracts obesity and glucose intolerance in a mouse model of glucocorticoid-induced metabolic syndrome
Liselotte Fransson, Cristiane dos Santos, Petra Wolbert, Åke Sjöholm, Alex Rafacho, Henrik Ortsäter · 2014 · Diabetology & Metabolic Syndrome
Adverse effects of incretin‐based therapies on major cardiovascular and arrhythmia events: meta‐analysis of randomized trials
Tiansheng Wang, Fei Wang, Junwen Zhou, Huilin Tang, Sharon Giovenale · 2016 · Diabetes/Metabolism Research and Reviews
The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
Helena W. Rodbard · 2018 · Diabetes Technology & Therapeutics
Composite endpoints in trials of type‐2 diabetes
Thomas Ray Einarson, Mohit Garg, V. Kaur, Michiel E. H. Hemels · 2013 · Diabetes Obesity and Metabolism
Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long‐Acting, Potent Glucagon‐Like Peptide‐1 Analog
Jerry D. Meece · 2009 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Stephen Brunton · 2009 · Postgraduate Medicine
The Role of Basal Insulin and Glucagon-Like Peptide-1 Agonists in the Therapeutic Management of Type 2 Diabetes—A Comprehensive Review
Garg, Satish K. · 2010 · Diabetes Technology & Therapeutics
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
R. Keith Campbell, Joshua J. Neumiller · 2010 · Diabetes Metabolic Syndrome and Obesity
Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden
Ali Kiadaliri, Ulf‐G. Gerdtham, Björn Eliasson, Katarina Steen Carlsson · 2014 · Diabetes Therapy
Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes
Louis Kuritzky, Guillermo E. Umpierrez, J.M. Ekoé, Leonardo Guadalupe Mancillas‐Adame, Laura Fernández Landó · 2014 · Postgraduate Medicine
Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Swati Srivastava, G N Saxena, Prakash Keshwani, Ritesh Gupta · 2012 · PubMed
Liraglutide prevents diabetes progression in prediabetic OLETF rats
Nanjing Guo, Jia Man Sun, Hong Chen, Hua Zhang, Zhen Zhang, De-hong Cai · 2012 · Endocrine Journal
Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats
M.J. Hall, Christopher A. Adin, Sofia Borin‐Crivellenti, Adam Joseph Rudinsky, Päivi J. Rajala‐Schultz, Jeffrey Lakritz, Chen Gilor · 2014 · Domestic Animal Endocrinology
Determining Predictors of Early Response to Exenatide in Patients with Type 2 Diabetes Mellitus
Muhammad Arif Khan, Jing Ouyang, Karen Perkins, Sunil Nair, Franklin Joseph · 2015 · Journal of Diabetes Research
GLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes
Jens Juul Holst, Yutaka Seino · 2009 · Diabetes Research and Clinical Practice
An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
Krystal L. Edwards, Megan Stapleton, Jessica Weis, Brian K. Irons · 2012 · Diabetes Technology & Therapeutics
The influence of age and metformin treatment status on reported gastrointestinal side effects with liraglutide treatment in type 2 diabetes
Ken Y Thong, Piya Sen Gupta, Andrew D. Blann, Robert E. J. Ryder · 2015 · Diabetes Research and Clinical Practice
Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus
Kaustubh Nisal, Ram Kela, Kamlesh K. Khunti, Melanie Jane Davies · 2012 · BMC Medicine
Cardiovascular outcomes of liraglutide in patients with type 2 diabetes
Chunmei Duan, Teng-Fei Wan, Yue Wang, Qingwu Yang · 2019 · Medicine
A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Hidekatsu Yanai, Mariko Hakoshima, Hiroki Adachi, Hisayuki Katsuyama · 2022 · Cardiology Research
GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment
Justin Wan, Caesar Ferrari, Micheal S. Tadros · 2024 · Gastroenterology Insights
Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity
Vanessa Preumont, Michel Paul Hermans, Sonia M. Brichard, Martin Buysschaert · 2010 · Diabetes & Metabolism
Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes
Fernando Ovalle · 2011 · Clinical Therapeutics
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Eugene E. Wright, Anthony H. Stonehouse, Robert M Cuddihy · 2010 · Diabetes Obesity and Metabolism
Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials
Michelle Elaine Orme, Hiep P. Nguyen, Jackie Lu, Susan V. Thomas · 2017 · Diabetes Metabolic Syndrome and Obesity
Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes
Riccardo Candido, Sara Gaiotti, Fabiola Giudici, Barbara Toffoli, Federica De Luca, Valerio Velardi, Alessandra Petrucco, Chiara Gottardi, Elena Manca, Iris Buda et al. · 2023 · Journal of Clinical Medicine
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
Sean D. Sullivan, Rafael Alfonso‐Cristancho, Chris Conner, Mette Hammer, Lawrence Blonde · 2009 · Cardiovascular Diabetology
Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?
I. W. Campbell · 2010 · International Journal of Clinical Practice
A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
Eduard Montanya · 2012 · Expert Opinion on Pharmacotherapy
Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes
Louis S. Matza, Kristina Secnik Boye, Brooke M. Currie, Rosirene Paczkowski, Laura Fernández Landó, Reema Mody, Jessica B. Jordan · 2018 · Current Medical Research and Opinion
Are peptide conjugates the golden therapy against obesity?
S J Brandt, Maximilian Kleinert, M H Tschöp, T D Müller · 2018 · Journal of Endocrinology
Liraglutide for the Treatment of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials
Du, Qiang, Wang, Yan-Jun, Yang, Sheng, Zhao, Yue-Yang, Han, Ping · 2014 · Advances in Therapy
The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis
Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, Chao‐Ming Hung, Andre Ferrer Carvalho, Brendon Stubbs, Yen‐Wen Chen, Tien‐Yu Chen, Wei‐Te Lei, Jiann-Jy Chen et al. · 2025 · BMC Medicine
GLP-1 receptor agonists and blood pressure: a state-of-the-art review of mechanisms, evidence, and clinical implications
Moiz, Areesha, Zolotarova, Tetiana, Filion, Kristian B, Eisenberg, Mark J · 2026 · American Journal of Hypertension
Targeting the gastrointestinal tract to treat type 2 diabetes
Paige V. Bauer, Frank Anthony Duca · 2016 · Journal of Endocrinology
The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials
Jianqiu Gu, Meng Xin, Yan Ping Guo, Lei Wang, Hongzhi Zheng, Yixuan Liu, Bingshu Wu, Difei Wang · 2016 · Scientific Reports
Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin
Katarina Steen Carlsson, Ulf Persson · 2014 · Journal of Medical Economics
C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment
Michinori Takabe, Tomokazu Matsuda, Yushi Hirota, Naoko Hashimoto, Tomoaki Nakamura, Kazuhiko Sakaguchi, Wataru Ogawa, Susumu Seino · 2012 · Diabetes Research and Clinical Practice
Emerging GLP-1 receptor agonists
Asger Lund, Filip Krag Knop, Tina Vilsbøll · 2011 · Expert Opinion on Emerging Drugs
The association between postprandial urinary C‐peptide creatinine ratio and the treatment response to liraglutide: a multi‐centre observational study
Ken Y Thong, Timothy James McDonald, Andrew Tym Hattersley, Andrew D. Blann, Shenaz Ramtoola, Catriona Duncan, Susan Venn Carr, Karen Adamson, AU Nayak, Reena Khurana et al. · 2013 · Diabetic Medicine
Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study
On behalf of the NN2211-4118 Study Group, Annunziata Lapolla, Cesare Berra, Massimo Boemi, Antonio Carlo Bossi, Riccardo Candido, Graziano Di Cianni, Simona Frontoni, Stefano Genovese, Paola Ponzani et al. · 2017 · Advances in Therapy
Liraglutide for psychiatric disorders: clinical evidence and challenges
Mehmet Akif Camkurt, Luca Lavagnino, Xiang Y. Zhang, Antônio Lúcio Teixeira · 2018 · Hormone Molecular Biology and Clinical Investigation
Emerging role of GLP-1 receptor agonists in the treatment of obesity
Lisa Neff · 2010 · Diabetes Metabolic Syndrome and Obesity
Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial
Kohei Kaku, Arihiro Kiyosue, Yuri Ono, Toshihiko Shiraiwa, Shizuka Kaneko, Keiji Nishijima, Heidrun Bosch‐Traberg, Yutaka Seino · 2015 · Journal of Diabetes Investigation
Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction
Leon I. Igel, Katherine H. Saunders, Joseph Jack Fins · 2018 · Current Atherosclerosis Reports
Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation
Ella Fung, Liya Kang, Diana Sapashnik, Susan Benard, Annette Sievers, Yan Liu, Guoying Grace Yan, Jing Wen Zhou, Linette Rodriguez, Weijun Ma et al. · 2021 · Scientific Reports
Pancreatitis with Pancreatic Tail Swelling Associated with Incretin-based Therapies Detected Radiologically in Two Cases of Diabetic Patients with End-Stage Renal Disease
Hirosuke Nakata, Seita Sugitani, Shuhei Yamaji, Satoko Otsu, Yoshihito Higashi, Yumiko Ohtomo, Gen Inoue · 2012 · Internal Medicine
Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion
Antonio Rotondò, Pieter Janssen, Flavia Mulè, Jan F. Tack · 2012 · International Journal of Obesity
Liraglutide for the Treatment of Type 2 Diabetes
Kyle R. Peters · 2011 · American Journal of Therapeutics